Navigation Links
Wellmune WGP supplementation alleviates
Date:4/8/2008

SAN DIEGO, CA. April 9, 2008 Wellmune WGP, a natural immune-enhancing ingredient from Biothera, reduced the incidence of fever and eliminated the need for study subjects to miss work or school due to the cold-like symptoms, researchers reported today at the 2008 Experimental Biology annual meeting.

Don Cox, Ph.D., Vice President of Research & Development for Biotheras Healthcare Group, said, This studys results are exciting because they show the potential for Wellmune WGP to naturally enhance the bodys innate immune response to protect against and ameliorate the symptoms of something that every one of us encountersthe common cold. These results are consistent with numerous other immune health studies conducted with our ingredient, and indicate the real-life benefits that Wellmune WGP supplementation can provide.

The research will be presented at the Poster Sessions starting 9:00 am on April 9th by Douglas Kalman, Ph.D., RD, FACN, a Director at Miami Research Associates, which conducted the study for Biothera. An abstract of the study is available at www.biothera.com/healthcare.

The double-blind, placebo-controlled study was conducted during the cold season with 40 healthy subjects, aged 18-65. The subjects were treated daily with either 250mg of Wellmune WGP or a placebo for 90 days. Wellmune WGP is a natural carbohydrate that activates key immune cells, including macrophages and neutrophils, to more quickly recognize and kill foreign challenges. The product engages the bodys natural defenses to promote health, wellness and vitality. In contrast with the placebo group, study participants who received Wellmune WGP daily reported:

  • No incidence of medically verified fever.

  • An increase in general health markers, including physical energy and emotional well-being, as measured by a clinically validated health survey questionnaire (SF-36v-2).

  • No need to take a sick day off of work or school (compared with 1.38 days of work/school missed for the placebo group).

In addition, although there were no differences between groups in the number of colds, at the end of the 12-week test period the Wellmune WGP-supplemented group exhibited significant improvements in Physical Component Summary scores as defined in the SF-36v-2 health survey.


'/>"/>

Contact: Dave Walsh
651-256-4606
Strategic Communications
Source:Eurekalert

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... LONDON , March 2, 2017 Who ... infringement lawsuits? Download the full report: https://www.reportbuyer.com/product/4313699/ ... ON THE FINGERPRINT SENSOR FIELD? Fingerprint sensors using ... smartphones. The fingerprint sensor vendor Idex forecasts an increase ... in mobile devices and of the fingerprint sensor market ...
(Date:3/1/2017)... BEDFORD, Mass. , March 1, 2017  Aware, ... and services, announced that Richard P. Moberg ... Officer and co-President and Chief Financial Officer and Treasurer ... will continue to serve as a member of the ... T. Russell , Aware,s co-Chief Executive Officer and co-President, ...
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant ... At PTE ... March, Materna will present its complete end-to-end passenger journey, ... real benefit for passengers. To accelerate the whole passenger handling ... solutions to take passengers through the complete integrated process with ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... ROCKVILLE, Md. , March 24, 2017  Infectex ... Fund (MBVF), today announced positive results of a Phase ... drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis ... by scientists at Sequella, Inc. ( USA ... A total of 140 patients were enrolled ...
(Date:3/24/2017)... -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with ... today announced participation at the following conferences: ... Maidstone Life Sciences conference "Cancer Immunotherapy Conference" at the ... York, NY . Agenus will participate in three ... Robert B. Stein , M.D., Ph.D., President, R&D ...
(Date:3/23/2017)... March 23, 2017  SeraCare Life Sciences, ... in vitro diagnostics manufacturers and clinical laboratories, ... first multiplexed Inherited Cancer reference material ... by next-generation sequencing (NGS). The Seraseqâ„¢ Inherited Cancer ... input from industry experts to validate the ...
(Date:3/23/2017)... 2017 NetworkNewsWire Editorial Coverage  ... Cancer remains one ... on health care systems, in terms of costs and resources. ... does the development of innovative and efficient therapies that demonstrate ... many types of cancer treatments, a growing number of patients ...
Breaking Biology Technology: